Login to Your Account



Clinic Roundup


Thursday, November 1, 2012

• Dynavax Technologies Corp., of Berkeley, Calif., said it will advance AZD1419, a second-generation Toll-like receptor 9 agonist for asthma, into Phase I studies.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription